New Risk • May 20
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.6b free cash flow). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥2.12b market cap, or US$13.3m). Ankündigung • May 15
Delta-Fly Pharma, Inc., Annual General Meeting, Jun 26, 2026 Delta-Fly Pharma, Inc., Annual General Meeting, Jun 26, 2026. Ankündigung • Feb 03
Delta-Fly Pharma, Inc. announced that it has received ¥1.68 million in funding from Macquarie Bank Limited On February 2, 2026, Delta-Fly Pharma, Inc. closed the transaction. The company announced that it has disclosed the returning investor Macquarie Bank Limited New Risk • Jan 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.6b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥6.20b market cap, or US$39.5m). Ankündigung • Dec 27
Delta-Fly Pharma, Inc. to Report Q3, 2026 Results on Feb 13, 2026 Delta-Fly Pharma, Inc. announced that they will report Q3, 2026 results on Feb 13, 2026 Ankündigung • Sep 27
Delta-Fly Pharma, Inc. to Report Q2, 2026 Results on Nov 14, 2025 Delta-Fly Pharma, Inc. announced that they will report Q2, 2026 results on Nov 14, 2025 New Risk • Aug 11
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.8b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.8b free cash flow). Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (JP¥6.58b market cap, or US$44.5m). Ankündigung • Jun 27
Delta-Fly Pharma, Inc. to Report Q1, 2026 Results on Aug 08, 2025 Delta-Fly Pharma, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025 Ankündigung • May 15
Delta-Fly Pharma, Inc., Annual General Meeting, Jun 26, 2025 Delta-Fly Pharma, Inc., Annual General Meeting, Jun 26, 2025. Ankündigung • Apr 30
Delta-Fly Pharma, Inc. announced that it has received ¥252.5515 million in funding from Macquarie Bank Limited On April 30, 2025, Delta-Fly Pharma, Inc closed the transaction. The company issued 24,300 units of stock acquisition rights at ¥105 per unit for aggregate gross proceeds of ¥2,551,500 and Zero coupon 2nd Series, non convertible, unsecured bonds at a price of ¥100 per bond for aggregate gross proceeds of ¥250,000,000. The bonds have a conversion price of ¥100 and a maturity date of April 30, 2027. Ankündigung • Mar 07
Delta-Fly Pharma, Inc. to Report Fiscal Year 2025 Results on May 15, 2025 Delta-Fly Pharma, Inc. announced that they will report fiscal year 2025 results on May 15, 2025 Ankündigung • Feb 28
Delta-Fly Pharma, Inc. Announces Progress of Development Status of the Combination Study of Dfp-10917 with Venetoclax Delta-Fly Pharma, Inc. announced that regarding the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) in second-line therapy (NCT06382168), the Data Management Committee (DMC) has approved the tolerability of all six patients in the Phase I (dose finding) portion of the Phase I/II study, and are moving to the Phase II portion of the trial for efficacy testing as of February 28, 2025. New Risk • Feb 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.7b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.7b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 5.4% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (JP¥5.70b market cap, or US$37.4m). New Risk • Jan 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 3.8% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (JP¥5.13b market cap, or US$33.0m). Ankündigung • Dec 10
Delta-Fly Pharma Inc. Provides Update for Development Status of the Combination Study of DFP-10917 with Venetoclax Delta-Fly Pharma, Inc. announced that the data review committee has approved the tolerability of the first three patients enrolled in the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (NCT06382168) conducted at five US clinical sites for patients with acute myeloid leukemia (who have failed/relapsed after standard VEN therapy (first-line therapy). Additionally, the bone marrow cell count in peripheral blood in all three cases was 0 (zero) within 4 weeks of starting treatment, and complete remission (CR or CRi) was confirmed by subsequent bone marrow biopsy. Three more patients will be added at the current dosage regimen, and after confirmation of the tolerability, the study will move to Phase II. Complete remission has been observed in patients who have failed/relapsed after existing VEN combination therapy (first-line therapy), so this is expected to be a new, highly effective second-line therapy for patients with AML. As previously reported, the data cleaning processes for interim analysis are currently underway for Phase III comparative clinical trial (150 cases) of DFP-10917 monotherapy targeting patients with AML receiving third-line or later therapy. Once this is completed, the results will be submitted to the Independent Data Safety Monitoring Committee (DSMB) along with electrocardiogram and pharmacokinetic study results for their advice. Ankündigung • Dec 05
Delta-Fly Pharma, Inc. to Report Q3, 2025 Results on Feb 14, 2025 Delta-Fly Pharma, Inc. announced that they will report Q3, 2025 results on Feb 14, 2025 Ankündigung • Dec 04
Delta-Fly Pharma Inc. Provides Update for Development Status of DFP-17729 Delta-Fly Pharma, Inc. announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved. In a Phase I/II study of DFP-17729 in combination with TS-1 in patients with end-stage pancreatic cancer, no significant difference was observed against the control treatment (TS-1 or gemcitabine), but stratified analysis showed that when patients in the third-line or later treatment were treated for more than 6 weeks, DFP-17729 in combination with TS-1 showed a predominant median overall survival (mOS) prolongation (9.0 months vs. 6.1 months) and a significant correlation was also observed between urinary alkalinization and mOS in pancreatic cancer patients treated with DFP-17729, as key proof of concept. Had presented these results at the ESMO Gastrointestinal Cancers Congress 2024 and the 55 Annual Meeting of the Japan Pancreas Society, where much attention was paid to the presentation. DFP-17729 is a novel approach to neutralize the acidic cancer microenvironment, and several patents on related inventions have been granted in major countries around the world, and its potential of efficacy has been published in peer-reviewed journals. first identify DFP-17729 as a treatment for refractory pancreatic cancer, for which effective treatment is not yet available, and then seek to expand the indication to other types of cancer through partnership with major global pharmaceutical companies. Ankündigung • Nov 26
Delta-Fly Pharma, Inc. Announces Progress Update of the Phase III Clinical Trial of DFP-14323 Delta-Fly Pharma, Inc. announced that Afatinib, which is being treated with DFP-14323 in ongoing Phase III clinical trial, has been approved by the Japanese Lung Cancer Society in its “Lung Cancer Treatment Guidelines 2024” (issued on October 20, 2024) as a first-line treatment for EGFR mutation-positive (uncommon mutation) non-small cell lung cancer (NSCLC), with a stronger recommendation than Osimertinib. The development of DFP-14323 is being conducted in patients (stage III/IV) with epidermal growth factor receptor (EGFR) mutation-positive uncommon mutation NSCLC in a Phase III clinical trial (superiority study) comparing DFP-14323 in combination with Afatinib (20 mg/day) and Afatinib (40 mg/day) alone. The strongly recommended treatment with afatinib as first-line therapy must accelerate the enrollment of NSCLC patients through this trial. The study is being conducted at 30 core hospitals throughout Japan involved in the treatment of NSCLC, and clinical efficacy will be finally determined by progression-free survival (PFS). DFP-14323 is a small molecule substance (oral absorption rate of approximately 100%) that inhibits the CD13/APN receptor, which is frequently found on cells in NSCLC including cancer stem cells. Ankündigung • Nov 05
Delta-Fly Pharma Inc Provides Update for Expanded Phase I Study of DFP-14927 As informed dated October 28, an interim analysis for the Phase III study ofDFP-10917 in R/R AML patients is ongoing. The Phase I/II combination study of DFP-10917 with Venetoclax in AML patients is well ongoing. Today, Delta-Fly Pharma, Inc. to talk about an update for development of the drug delivery of DFP-10917 selective to solid tumor, which is namely, DFP-14927 showed nice safety and efficacy in the Phase I study in solid tumor patients. Accordingly, company have moved forward into an expanded Phase I study of DFP-14927 at 3200 mg/m weekly dosing in R/R colorectal cancer patients at MD Anderson Cancer Center and UCLA. Efficacy in expanded Phase I study is evaluated by Disease Control Ratio (DCR) and it shall be evaluated by OS in the next registration study for NDA approval. Ankündigung • Oct 28
Delta-Fly Pharma Inc. announces Phase I/II Study of Dfp-10917 and Venetoclax in Aml Patients Begins with Promising Initial Data Delta-Fly Pharma, Inc. announced that following to the previous information on September 10th. 2024, the company share latest development status. Enrollment of patients is progressing smoothly into the Phase I portion of the Phase I/II study of DFP-10917 combined with Venetoclax in AML patients previously treated with Venetoclax, one regimen. The first three patients are showing encouraging safety and efficacy results suggested further promising development. The existing standard combination chemotherapy for AML patients is Azacitidine and Venetoclax, but it is not comfortable for AML patients. We’re trying to do a combination of DFP-10917 with Venetoclax, as an alternative safer AML therapy, objective NDA approval from the FDA in the US under possible collaboration with a global mega-pharma. The Phase III study of DFP-10917 in relapsed/refractory AML patients is planned data cut-off as decreasing in the number of long-term survivors since then. Ankündigung • Aug 28
Delta-Fly Pharma, Inc. to Report Q2, 2025 Results on Nov 14, 2024 Delta-Fly Pharma, Inc. announced that they will report Q2, 2025 results on Nov 14, 2024 New Risk • Aug 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 3.4% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (JP¥4.71b market cap, or US$31.9m). Ankündigung • Jul 03
Delta-Fly Pharma, Inc. Announces Enrollment of Patients in the Phase III Clinical Trial of DFP-14323 Delta-Fly Pharma, Inc. announced that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/day) versus Afatinib (40 mg/day) alone in stage III/IV non-small cell lung cancer patients with uncommon EGFR mutation positive that was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Feb. 2024, has started as of July 3, 2024 in Japan. This Phase III clinical trial will be conducted at 30 sites with NSCLC experts in Japan and the superiority of the add-on effect of DFP-14323 on progression-free survival (PFS) as primary endpoint will be confirmed. As DFP-14323 selectively binds to the aminopeptidase N, which is widely expressed on various cells, as lung cancer and inflammatory cells, it is expected to be effective in the treatment of patients with refractory cancer and when the superiority of the add-on effect can be confirmed in this study, it is expected to provide a novel cancer immunotherapy that is independent of EGFR mutation types, uncommon or common mutation. The company will accelerate the progress of the trial by expanding this Phase III clinical trial outside of Japan to Asian countries with large numbers of EGFR mutation-positive non-small cell lung cancer patients, and at the same time, the company will promote out-licensing activities to Asian pharmaceutical companies. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Independent Outside Director Akifumi Taniguchi was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • Jun 02
Delta-Fly Pharma, Inc. to Report Q1, 2025 Results on Aug 09, 2024 Delta-Fly Pharma, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024 Ankündigung • May 17
Delta-Fly Pharma, Inc., Annual General Meeting, Jun 27, 2024 Delta-Fly Pharma, Inc., Annual General Meeting, Jun 27, 2024. Ankündigung • Apr 09
Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax Delta-Fly Pharma, Inc. shared latest development status. The company announced the protocol for the Phase I/II clinical trial of DFP-10917 combined with Venetoclax (VTX) in patients with acute myeloid leukemia (AML) with prior VTX involved one regimen, which was submitted to the FDA in US on March 8 has been approved by the FDA in US dated April 8, 2024. Accordingly, the company can start the Phase I/II combo-study very soon. The aim for conducting this study is to judge if DFP-10917 combined with VTX is to show superiority to the standard chemotherapy (azacitidine combined with VTX) for AML. This combo-study shall be done by major clinical sites in US like Wake Forest University, expertise with clinical study of novel chemotherapy for AML. The interim analysis of the Phase III trial of DFP-10917 monotherapy in patients with recurrent or refractory AML is under follow-up for a number of long-term survivors that have a significant impact on the overall survival (OS) analysis. Ankündigung • Mar 11
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax (VTX) in the AML Patients Treated by VTX in the AML Delta-Fly Pharma Inc. announced that FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen have been done on March 8th, 2024. The Phase I/II study ofDFP-10917 with VTX in the above AML patients shall be started at Wake Forest and the other hospitals soon after FDA approval. The interim analysis of the Phase III study of DFP-109 17 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US is undergoing for the reason there are patients with a long-term survival may effect on OS analysis. The invention with the combination of DFP-14927 with VTX in AML was granted in Japan, US, and Taiwan. Ankündigung • Mar 02
Delta-Fly Pharma, Inc. to Report Fiscal Year 2024 Results on May 15, 2024 Delta-Fly Pharma, Inc. announced that they will report fiscal year 2024 results on May 15, 2024 Ankündigung • Feb 04
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323 Delta-Fly Pharma, Inc. announced that as presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive in a Phase II clinical trial, has demonstrated fascinating longer median progression-free survival (mPFS; 23.1 months). Subsequently, based on these results, they have been in negotiation with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan with the aim of submitting a conditional approval application, resulting in decision to conduct a Phase III clinical trial (superiority study) of DFP-14323 in combination with afatinib (20 mg/day) versus afatinib (40 mg/day) alone in stage III/IV non-small cell lung cancer patients with uncommon EGFR mutation positive based on the PMDA's recommendation. And finally, the company announced that the submission of the protocol for the Phase III study to the PMDA has been approved and are ready to initiate the study. This Phase III clinical trial will be conducted at 30 sites in Japan and if the superiority of the add-on effect of DFP-14323 on progression-free survival (PFS) as primary endpoint, is confirmed in this trial, they believe that DFP-14323 will be a novel cancer immunotherapy drug with highly beneficial for patients and their families, as it is orally available, safe, and economical. Furthermore, if non-inferiority to osimertinib (80 mg/day) can be confirmed in a comparative study, a huger market can be expected. Ankündigung • Jan 30
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML Delta-Fly Pharma, Inc. announced that the following is the current status of the interim analysis of a Phase III study of DFP-10917 monotherapy in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US. As there are a long-term surviving patients in the 150 patients enrolled in this study, the company intend to continue to follow up these patients without any data cut-off for the time being to determine the final overall survival (OS) results of the study. The company ask for understanding that under a randomized and controlled study, the company is unable to identify at this stage whether these surviving patients are in the DFP-10917 group or the control group (NCT03926624). The company look forward to showing the results when the data is ready to disclose. Ankündigung • Dec 28
Delta-Fly Pharma, Inc. to Report Q3, 2024 Results on Feb 13, 2024 Delta-Fly Pharma, Inc. announced that they will report Q3, 2024 results on Feb 13, 2024 New Risk • Dec 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 2.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥7.31b market cap, or US$51.4m). New Risk • Oct 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 1.3% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (JP¥6.22b market cap, or US$41.5m). Ankündigung • Sep 28
Delta-Fly Pharma, Inc. to Report Q2, 2024 Results on Nov 13, 2023 Delta-Fly Pharma, Inc. announced that they will report Q2, 2024 results on Nov 13, 2023 Ankündigung • Jun 28
Delta-Fly Pharma, Inc. to Report Q1, 2024 Results on Aug 14, 2023 Delta-Fly Pharma, Inc. announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Feb 17
Third quarter 2023 earnings released: JP¥75.09 loss per share (vs JP¥51.67 loss in 3Q 2022) Third quarter 2023 results: JP¥75.09 loss per share (further deteriorated from JP¥51.67 loss in 3Q 2022). Net loss: JP¥416.0m (loss widened 49% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Ankündigung • Dec 06
Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited On December 5, 2022, Delta-Fly Pharma, Inc. closed the transaction. Ankündigung • Nov 18
Delta-Fly Pharma, Inc. announced that it expects to receive ¥1.300842 billion in funding from Macquarie Group Limited Delta-Fly Pharma, Inc. announced a private placement of unsecured bonds for an aggregate gross proceeds of ¥1,300,842,000 on November 17, 2022. The transaction included participation from Macquarie Group Limited. The transaction has been approved by the board of directors of the company. Reported Earnings • Nov 16
First half 2023 earnings released: JP¥115 loss per share (vs JP¥103 loss in 1H 2022) First half 2023 results: JP¥115 loss per share (further deteriorated from JP¥103 loss in 1H 2022). Net loss: JP¥622.0m (loss widened 12% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Senior MD, Head of Research & Development and Director Kenzo Iizuka was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Aug 16
First quarter 2023 earnings released: JP¥56.83 loss per share (vs JP¥56.58 loss in 1Q 2022) First quarter 2023 results: JP¥56.83 loss per share (down from JP¥56.58 loss in 1Q 2022). Net loss: JP¥308.0m (flat on 1Q 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Ankündigung • May 18
Delta-Fly Pharma, Inc., Annual General Meeting, Jun 29, 2022 Delta-Fly Pharma, Inc., Annual General Meeting, Jun 29, 2022. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Senior MD, Head of Research & Development and Director Kenzo Iizuka was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Ankündigung • Apr 08
Delta-Fly Pharma, Inc. to Report Fiscal Year 2022 Results on May 13, 2022 Delta-Fly Pharma, Inc. announced that they will report fiscal year 2022 results on May 13, 2022 Is New 90 Day High Low • Mar 05
New 90-day low: JP¥1,067 The company is down 35% from its price of JP¥1,653 on 04 December 2020. The Japanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period. Is New 90 Day High Low • Jan 29
New 90-day low: JP¥1,119 The company is down 50% from its price of JP¥2,233 on 30 October 2020. The Japanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 12% over the same period. Is New 90 Day High Low • Dec 08
New 90-day low: JP¥1,521 The company is down 35% from its price of JP¥2,330 on 09 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. 